Kunming Longjin Pharmaceutical Co., Ltd.

As of March 31, 2025, Kunming Longjin Pharmaceutical Co., Ltd. has 400.50M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 12.35, and the price-to-book ratio stands at 1.37.

These figures are as of March 31, 2025. The EV/Sales ratio of 6.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Kunming Longjin Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 19.57, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2025, Kunming Longjin Pharmaceutical Co., Ltd. maintains a current ratio of 7.94, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.53, indicating moderate leverage, while an interest coverage ratio of -127.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Kunming Longjin Pharmaceutical Co., Ltd. posted a negative return on equity (ROE) of -9.41, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.86, reflecting losses generated across the asset base. Inventory turnover of 0.69 indicates how many times Kunming Longjin Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 27, 2025, Kunming Longjin Pharmaceutical Co., Ltd.'s stock has declined approximately 61.44% over the past 52 weeks. The 50-day moving average sits at 0.99, while the 200-day moving average is 1.75.

Over the twelve months ended March 31, 2025, Kunming Longjin Pharmaceutical Co., Ltd. posted a gross margin of 61.49, reflecting its pricing power and cost economics. The operating margin of -59.86 and net profit margin of -89.21 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. The dividend payout ratio of -0.13 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.85, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.82, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Kunming Longjin Pharmaceutical Co., Ltd. shareholders.

Kunming Longjin Pharmaceutical Co., Ltd.'s most recent stock split took place on May 18, 2016 with a 1:2 split ratio.

As of March 31, 2025, Kunming Longjin Pharmaceutical Co., Ltd. has an Altman Z-Score of 5.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.